Borderline personality disorder in patients with bipolar disorder and response to lamotrigine (Q44801078)

6 December 2017

title

Borderline personality disorder in patients with bipolar disorder and response to lamotrigine (English)

1 reference

borderline personality disorder

6 December 2017

main subject

0 references

1 reference

Gilbert A Preston

1

1 reference

6 December 2017

Barrie K Marchant

2

1 reference

6 December 2017

Fredrick W Reimherr

3

1 reference

6 December 2017

Robert E Strong

4

1 reference

6 December 2017

Dawson W Hedges

5

1 reference

6 December 2017

publication date

1 April 2004

1 reference

Journal of Affective Disorders

6 December 2017

published in

1 reference

6 December 2017

volume

79

1 reference

6 December 2017

issue

1-3

1 reference

6 December 2017

page(s)

297-303

1 reference

Treatment utilization by patients with personality disorders.

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

The efficacy of lamotrigine in rapid cycling and non–rapid cycling patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

Personality traits and disorder in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

Personality disorders in first- and multiple-episode mania

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

The long-term natural history of the weekly symptomatic status of bipolar I disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

PDQ-R personality disorders in bipolar patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

Developmental vulnerabilities to the onset and course of bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

Comorbidity of attention deficit hyperactivity disorder with early- and late-onset bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

Risperidone in comorbid borderline personality disorder and dysthymia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900358-0

7 January 2021

10.1016/S0165-0327(02)00358-0

Identifiers

DOI

1 reference

6 December 2017

1 reference